

# Mary Philip

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1195206/publications.pdf>

Version: 2024-02-01

23  
papers

4,157  
citations

623734

14  
h-index

752698

20  
g-index

23  
all docs

23  
docs citations

23  
times ranked

7038  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining T cell exhaustion™. Nature Reviews Immunology, 2019, 19, 665-674.	22.7	879
2	TOX is a critical regulator of tumour-specific T cell differentiation. Nature, 2019, 571, 270-274.	27.8	697
3	Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature, 2017, 545, 452-456.	27.8	643
4	Inflammation as a tumor promoter in cancer induction. Seminars in Cancer Biology, 2004, 14, 433-439.	9.6	556
5	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity, 2016, 45, 389-401.	14.3	496
6	CD8+ T cell differentiation and dysfunction in cancer. Nature Reviews Immunology, 2022, 22, 209-223.	22.7	345
7	Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase. Journal of Experimental Medicine, 2010, 207, 2469-2477.	8.5	116
8	Microenvironmental Metabolism Regulates Antitumor Immunity. Cancer Research, 2019, 79, 4003-4008.	0.9	91
9	Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. Current Opinion in Immunology, 2019, 58, 98-103.	5.5	83
10	TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. Journal of Experimental Medicine, 2022, 219, .	8.5	64
11	Alterations of T-cell-mediated immunity in acute myeloid leukemia. Oncogene, 2020, 39, 3611-3619.	5.9	52
12	Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. Blood, 2016, 128, 1834-1834.	1.4	42
13	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematology, 2021, 8, e562-e571.	4.6	28
14	Heme Exporter FLVCR Is Required for T Cell Development and Peripheral Survival. Journal of Immunology, 2015, 194, 1677-1685.	0.8	26
15	Viral and cellular oncogenes promote immune evasion. Oncogene, 2022, 41, 921-929.	5.9	12
16	TLR Stimulation Dynamically Regulates Heme and Iron Export Gene Expression in Macrophages. Journal of Immunology Research, 2016, 2016, 1-10.	2.2	9
17	Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4 <sup>+</sup> T cells. Immunology, 2010, 130, 494-503.	4.4	7
18	Bendamustine with rituximab, etoposide and carboplatin (TREC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. British Journal of Haematology, 2018, 183, 601-607.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance. Trends in Immunology, 2015, 36, 665-667.	6.8	2
20	CD226 Throttles up CD8+ T Cell Antitumor Activity. Immunity, 2020, 53, 704-706.	14.3	2
21	FLVCR, a Heme Exporter, Is Required for Peripheral T Cell Survival.. Blood, 2012, 120, 2162-2162.	1.4	0
22	Full Dose Bendamustine (Treanda Â®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma. Blood, 2012, 120, 3650-3650.	1.4	0
23	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. Blood, 2016, 128, 861-861.	1.4	0